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Background
Allergic sensitization has been linked to active and passive
smoking in exposed individuals and even their pets. We
here investigated the contribution of acrolein, a compound
generated in large amounts during smoking, during nasal
sensitization and – based on the surprising preliminary
results – on tumor growth. As a model antigen we used
KLH with or without acrolein.
Methods
BALB/c mice were nasally sensitized 5 times in biweekly
intervals with KLH alone or with KLH in conjunction
with acrolein. Airway hyperreactivity was was measured
according to change of enhanced pause and KLH-specific
anaphylactic reaction was monitored in vivo Levels of
specific antibodies as well as cytokine profile of KLH-sti-
mulated splenocytes were analyzed by ELISA. Further,
mouse D2F2-tumor cells were grafted to the flanks and
tumor growth monitored in mice previously exposed to
acrolein or buffer.
Results
Nasal application of KLH as model antigen induced spe-
cific IgG1-, IgG2a-, IgA- and IgE-levels. The same mice
secreted elevated levels of IL5, IL13, IL10 and IFN-g.
They showed increased airway-hyperreactivity and had a
significant drop in body temperature upon allergen chal-
lenge. Pointing towards tolerance, and against our
expectations, presence of acrolein in the KLH-antigen
significantly reduced specific antibody-titers, resulted in
lower splenocyte cytokine production and prevented
anaphylaxis. However, the impaired immune response
simultaneously led to a significantly higher tumor
growth in mice exposed to acrolein than in the control
group.
Conclusion
Acrolein in smoke – best known for its carcinogenic
effect - decreases the risk of sensitization towards a speci-
fic antigen by inhibiting immune activation. Our data
further suggest that Acrolein via the same mechanism
acts tumor promoting in smokers.
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